Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.65 and traded as low as $6.42. Karyopharm Therapeutics shares last traded at $6.51, with a volume of 45,358 shares trading hands.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on KPTI. Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. Finally, HC Wainwright lifted their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.50.
Check Out Our Latest Report on KPTI
Karyopharm Therapeutics Stock Performance
The firm has a market capitalization of $35.01 million, a price-to-earnings ratio of -4.08 and a beta of 0.11. The company has a 50-day moving average of $8.18 and a 200-day moving average of $10.48.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. As a group, analysts anticipate that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Velan Capital Investment Management LP acquired a new stake in Karyopharm Therapeutics in the 4th quarter valued at approximately $27,000. Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. bought a new position in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $32,000. Two Sigma Advisers LP raised its holdings in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock valued at $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP bought a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth $85,000. 66.44% of the stock is owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Read More
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
